Vigilant Capital Management LLC continued to hold its stake in shares of Celgene Corporation (NASDAQ:CELG) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,054 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. Vigilant Capital Management LLC’s holdings in Celgene Corporation were worth $397,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. State Street Corp lifted its position in Celgene Corporation by 2.3% during the first quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock valued at $4,040,668,000 after purchasing an additional 723,844 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Celgene Corporation by 4.9% during the first quarter. Bank of New York Mellon Corp now owns 10,088,473 shares of the biopharmaceutical company’s stock valued at $1,255,309,000 after purchasing an additional 472,067 shares in the last quarter. American Century Companies Inc. lifted its position in Celgene Corporation by 4.4% during the first quarter. American Century Companies Inc. now owns 6,563,791 shares of the biopharmaceutical company’s stock valued at $816,733,000 after purchasing an additional 276,089 shares in the last quarter. Pioneer Investment Management Inc. lifted its position in Celgene Corporation by 15.7% during the first quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock valued at $650,911,000 after purchasing an additional 710,584 shares in the last quarter. Finally, Clearbridge Investments LLC lifted its position in Celgene Corporation by 24.1% during the first quarter. Clearbridge Investments LLC now owns 4,601,919 shares of the biopharmaceutical company’s stock valued at $572,617,000 after purchasing an additional 892,392 shares in the last quarter. 79.33% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Vigilant Capital Management LLC Has $397,000 Holdings in Celgene Corporation (CELG)” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://www.watchlistnews.com/vigilant-capital-management-llc-has-397000-holdings-in-celgene-corporation-celg/1599295.html.

In other news, Director Ernest Mario sold 18,506 shares of Celgene Corporation stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the sale, the director now owns 69,424 shares of the company’s stock, valued at approximately $9,061,220.48. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Terrie Curran sold 1,727 shares of Celgene Corporation stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the sale, the insider now directly owns 3,925 shares in the company, valued at approximately $564,768.25. The disclosure for this sale can be found here. Insiders sold a total of 46,233 shares of company stock worth $6,268,259 over the last three months. Corporate insiders own 0.95% of the company’s stock.

Celgene Corporation (NASDAQ CELG) traded up 2.14% on Friday, hitting $145.82. The stock had a trading volume of 4,324,637 shares. The firm’s 50 day moving average price is $135.45 and its 200-day moving average price is $127.81. Celgene Corporation has a 12 month low of $96.93 and a 12 month high of $146.00. The stock has a market cap of $114.08 billion, a PE ratio of 45.16 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The business had revenue of $3.27 billion for the quarter, compared to analyst estimates of $3.23 billion. During the same period last year, the company posted $1.44 EPS. The business’s revenue was up 18.7% on a year-over-year basis. On average, analysts forecast that Celgene Corporation will post $7.32 EPS for the current year.

Several equities analysts recently weighed in on the company. BTIG Research downgraded Celgene Corporation from a “buy” rating to a “neutral” rating and lifted their target price for the company from $96.93 to $131.70 in a research report on Friday, June 30th. Vetr upgraded Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 target price on the stock in a research report on Thursday, August 10th. SunTrust Banks, Inc. set a $150.00 target price on Celgene Corporation and gave the company a “buy” rating in a research report on Thursday, July 6th. Canaccord Genuity set a $156.00 target price on Celgene Corporation and gave the company a “buy” rating in a research report on Thursday, July 27th. Finally, William Blair reiterated an “outperform” rating on shares of Celgene Corporation in a research report on Monday, June 26th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $150.31.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.